Multiregional Assessment of CIMP in Primary Colorectal Cancers: Phenotype Concordance but Marker Variability

Overview

Journal Int J Cancer

Specialty Oncology

Date 2020 Dec 7

PMID 33284993

Citations 6

Authors

Bjornar T B Flatin

Hege Marie Vedeld

Rita Pinto

Jonas Langerud

Guro E Lind

Ragnhild A Lothe

Anita Sveen

Marine Jeanmougin

Affiliations

Soon will be listed here.

Abstract

Intratumor heterogeneity of colorectal cancers (CRCs) is manifested both at the genomic and epigenomic levels. Early genetic aberrations in carcinogenesis are clonal and present throughout the tumors, but less is known about the heterogeneity of the epigenetic CpG island methylator phenotype (CIMP). CIMP characterizes a subgroup of CRCs thought to originate from specific precursor lesions, and it is defined by widespread DNA methylation within promoter regions. In this work, we investigated CIMP in two to four multiregional samples from 30 primary tumors (n = 86 samples) using the consensus Weisenberger gene panel (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1). Twenty-nine of 30 tumors (97%) showed concordant CIMP status in all samples, and percent methylated reference (PMR) values of all five markers had higher intertumor than intratumor variation (P value = 1.5e-09). However, a third of the CIMP+ tumors exhibited discrepancies in methylation status in at least one of the five gene markers. To conclude, CIMP status was consistent within primary CRCs, and it is likely a clonal phenotype. However, spatial discordances of the individual genes suggest that large-scale analysis of multiregional samples could be of interest for identifying CIMP markers that are robust to intratumor heterogeneity.

Citing Articles

An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer.

Shahzad M, Hameed H, Amjad A, Khan M, Qureshi I, Hameed A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39361171 DOI: 10.1007/s00210-024-03482-0.

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Trembath H, Yeh J, Lopez N Cancer Treat Res. 2024; 192:305-418.

PMID: 39212927 DOI: 10.1007/978-3-031-61238-1_15.

Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on F-FDG PET/CT for Patients with Colorectal Cancer.

Liu X, Xiang K, Geng G, Wang S, Ni M, Zhang Y Contrast Media Mol Imaging. 2022; 2022:2586245.

PMID: 35173559 PMC: 8818395. DOI: 10.1155/2022/2586245.

CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?.

Pawel K, Maria Malgorzata S Int J Mol Sci. 2022; 23(2).

PMID: 35055016 PMC: 8777692. DOI: 10.3390/ijms23020830.

From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome.

Lepore Signorile M, Disciglio V, Di Carlo G, Pisani A, Simone C, Ingravallo G Int J Mol Sci. 2021; 22(13).

PMID: 34201893 PMC: 8268977. DOI: 10.3390/ijms22136767.

References

Sottoriva A, Kang H, Ma Z, Graham T, Salomon M, Zhao J . A Big Bang model of human colorectal tumor growth. Nat Genet. 2015; 47(3):209-16. PMC: 4575589. DOI: 10.1038/ng.3214. View

Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

Samowitz W, Albertsen H, Herrick J, Levin T, Sweeney C, Murtaugh M . Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005; 129(3):837-45. DOI: 10.1053/j.gastro.2005.06.020. View

Juo Y, Johnston F, Zhang D, Juo H, Wang H, Pappou E . Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014; 25(12):2314-2327. PMC: 4239805. DOI: 10.1093/annonc/mdu149. View

Vedeld H, Merok M, Jeanmougin M, Danielsen S, Honne H, Presthus G . CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017; 141(5):967-976. PMC: 5518206. DOI: 10.1002/ijc.30796. View

Cohen S, Yu M, Baker K, Redman M, Wu C, Heinzerling T . The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. Clin Epigenetics. 2017; 9:46. PMC: 5414304. DOI: 10.1186/s13148-017-0347-1. View

Ogino S, Goel A . Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10(1):13-27. PMC: 2175539. DOI: 10.2353/jmoldx.2008.070082. View

Weisenberger D, Siegmund K, Campan M, Young J, Long T, Faasse M . CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38(7):787-93. DOI: 10.1038/ng1834. View

Jones H, Jenkins G, Williams N, Griffiths P, Chambers P, Beynon J . Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer. World J Surg. 2017; 41(5):1375-1383. PMC: 5394146. DOI: 10.1007/s00268-016-3860-z. View

10.

Huhns M, Krohn S, Murua Escobar H, Prall F . Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain?. Hum Pathol. 2018; 74:54-63. DOI: 10.1016/j.humpath.2017.12.015. View

11.

McGranahan N, Swanton C . Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015; 27(1):15-26. DOI: 10.1016/j.ccell.2014.12.001. View

12.

Flatin B, Vedeld H, Pinto R, Langerud J, Lind G, Lothe R . Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability. Int J Cancer. 2020; 148(7):1652-1657. PMC: 7898891. DOI: 10.1002/ijc.33425. View

13.

Brunsell T, Sveen A, Bjornbeth B, Rosok B, Danielsen S, Brudvik K . High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clin Colorectal Cancer. 2020; 19(1):e26-e47. DOI: 10.1016/j.clcc.2019.09.003. View

14.

Pharo H, Honne H, Vedeld H, Dahl C, Andresen K, Liestol K . Experimental factors affecting the robustness of DNA methylation analysis. Sci Rep. 2016; 6:33936. PMC: 5037394. DOI: 10.1038/srep33936. View

15.

Levine A, Phipps A, Baron J, Buchanan D, Ahnen D, Cohen S . Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):68-75. PMC: 4713308. DOI: 10.1158/1055-9965.EPI-15-0935. View

16.

Andor N, Graham T, Jansen M, Xia L, Aktipis C, Petritsch C . Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2015; 22(1):105-13. PMC: 4830693. DOI: 10.1038/nm.3984. View

17.

Ogino S, Kawasaki T, Kirkner G, Kraft P, Loda M, Fuchs C . Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007; 9(3):305-14. PMC: 1899428. DOI: 10.2353/jmoldx.2007.060170. View

18.

Weisenberger D, Campan M, Long T, Kim M, Woods C, Fiala E . Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005; 33(21):6823-36. PMC: 1301596. DOI: 10.1093/nar/gki987. View

19.

Fennell L, Dumenil T, Wockner L, Hartel G, Nones K, Bond C . Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas. Cell Mol Gastroenterol Hepatol. 2019; 8(2):269-290. PMC: 6699251. DOI: 10.1016/j.jcmgh.2019.04.002. View

20.

Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H . Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics. 2016; 8:25. PMC: 4776403. DOI: 10.1186/s13148-016-0191-8. View